524731 Stock Overview
Researches and develops, manufactures, and markets pharmaceutical and healthcare products in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Jenburkt Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹908.40 |
| 52 Week High | ₹925.00 |
| 52 Week Low | ₹586.90 |
| Beta | 0.64 |
| 11 Month Change | 1.83% |
| 3 Month Change | 21.75% |
| 1 Year Change | 22.98% |
| 33 Year Change | 81.32% |
| 5 Year Change | 113.21% |
| Change since IPO | 12,694.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524731 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.7% | 2.2% | -1.0% |
| 1Y | 23.0% | 46.7% | 43.6% |
Return vs Industry: 524731 underperformed the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: 524731 underperformed the Indian Market which returned 43.6% over the past year.
Price Volatility
| 524731 volatility | |
|---|---|
| 524731 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524731 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524731's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 752 | Ashish Bhuta | jenburkt.com |
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names.
Jenburkt Pharmaceuticals Limited Fundamentals Summary
| 524731 fundamental statistics | |
|---|---|
| Market cap | ₹4.01b |
| Earnings (TTM) | ₹259.77m |
| Revenue (TTM) | ₹1.42b |
15.4x
P/E Ratio2.8x
P/S RatioIs 524731 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524731 income statement (TTM) | |
|---|---|
| Revenue | ₹1.42b |
| Cost of Revenue | ₹313.42m |
| Gross Profit | ₹1.11b |
| Other Expenses | ₹846.48m |
| Earnings | ₹259.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 58.86 |
| Gross Margin | 77.92% |
| Net Profit Margin | 18.30% |
| Debt/Equity Ratio | 0% |
How did 524731 perform over the long term?
See historical performance and comparison